Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + Cetuximab
Phase 2CompletedDevelopment Stage
Head and Neck Cancer
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck
Dec 13, 2022 → Sep 22, 2025
About Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + Cetuximab
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + Cetuximab is a phase 2 stage product being developed by BioAtla for Head and Neck Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05271604. Target conditions include Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck.
What happened to similar drugs?
11 of 20 similar drugs in Head and Neck Cancer were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05271604 | Phase 2 | Completed |
Competing Products
20 competing products in Head and Neck Cancer